196results about How to "Reduce adverse side effects" patented technology

This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.

Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

The delivery systems of the present disclosure are configurable to administer either single-dose or multiple-doses of one or more substances to a user, for example to the eye, nose, mouth, ear or rectum of the user. The precise and repeatable dosing features of the presently disclosed delivery systems overcome many of the disadvantages associated with known methods for dispensing substances to, for example, the eye of a user. The delivery systems administer precise doses of a substance to a precise location from unit dosage forms that may be single-dose or multiple-dose unit dosage forms, which may be externally or internally pierced.

The invention provides sustained release formulations of basic drugs, stereoisomers of basic drugs, pharmaceutically acceptable salts of basic drugs, and pharmaceutically acceptable salts of stereoisomers of basic drugs. The basic drugs may be anti-dementia drugs, such as cholinesterase inhibitors or memantine. In one embodiment, the cholinesterase inhibitor is donepezil.

Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided.

An object of the present invention is to provide a patch-containing packaging pouch which enables stable storage of a patch containing bisoprolol in a pressure-sensitive adhesive layer. A packaged desiccant 1 of the present invention has a packaging pouch 8 composed of a pair of laminated package members 7a and 7b arranged in mutual opposition, and a patch 10 housed in the space within this packaging pouch 8. Patch 10 is provided with a support 12 and a pressure-sensitive adhesive layer 14 laminated substantially over the entire surface of one side of this support 12. In addition, the pressure-sensitive adhesive layer is composed of a pressure-sensitive adhesive composition containing a pressure-sensitive adhesive and bisoprolol or pharmaceutically acceptable salt thereof. Moreover, a packaged desiccant 20 is housed within packaging pouch 8. The relative humidity within packaging pouch 8 is maintained at 25% or less in a patch-containing packaging pouch 1 having this constitution.

The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.

This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formulawherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, -O-, -S(O)m- (wherein m is 0, 1 or 2) or -N(R4)- (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

A cyclic dinucleotide compound of Formula (I):

wherein X₁ is H or F; X₂ is H or F; at least one among X₁ and X₂ is a fluorine atom; Z is OH, OR₁, SH or SR₁, wherein: R₁ is Na or NH₄, or R₁ is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B₁ and B₂ are bases chosen from Adenine, Hypoxanthine or Guanine, and B₁ is a different base than B₂ and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof:

wherein

• [0001]
  • R¹ and R² are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR⁵;
  [0002]
  • or R¹ and R², taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group;
  [0003]
  • X and Y are independently selected from O, S, NH, and (CR⁶R⁷)_n;
  [0004]
  • R³ is hydrogen, alkyl or M⁺; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof;
  [0005]
  • Z is N or CR⁴;
  [0006]
  • R⁴ is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR⁵;
  [0007]
  • R⁵ is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl;
  [0008]
  • R⁶ and R⁷ are independently selected from hydrogen and alkyl; n is an integer from 1 to 6;
  [0009]
  • at least one of R¹, R² and R⁴ is other than hydrogen; and
  [0010]
  • at least one of X and Y is (CR⁶R⁷)_n. D-serine or cycloserine may be coadministered along with the compound of formula I.

Methods are provided for classification of cancers by the expression of a set of genes referred to as the core serum response (CSR), or a subset thereof. The expression pattern of the CSR in normal tissues correlates with that seen in quiescent fibroblasts cultured in the absence of serum, while cancer tissues can be classified as having a quiescent or induced CSR signature. Patients with the induced CSR signature have a higher probability of metastasis. Classification according to CSR signature allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like.

The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

The invention discloses fuscoporia obliqua active ingredients capable of lowering blood sugar and a preparation method and application of the fuscoporia obliqua active ingredients. The preparation method takes fuscoporia obliqua fruit body as raw material and comprises the following steps: respectively extracting, filtering and concentrating the fuscoporia obliqua fruit body with normal temperature water and high temperature water; adding alcohol into concentrate and depositing to obtain crude polysaccharide; respectively pouring the polysaccharide extracted with normal temperature water and the crude polysaccharide extracted with high temperature water to flow through a (diethylaminoethanol) DEAE-52 cellulose column; carrying out subsection elution by using distilled water and NaCl solutions with different concentrations; and collecting stepwise elution peak sugar solution. Internal blood sugar reduction activity experiment shows that 0.2mol/L NaCl-section eluted sugar of the crude polysaccharide extracted with normal temperature water and 0.2mol/L NaCl-section eluted sugar of the crude polysaccharide extracted with high temperature water both have obvious blood sugar reduction activity, same blood sugar reduction activity with the blood sugar reduction medicine of metformin hydrochloride, and no obvious toxic or side effect.

The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

The invention relates to the detection and/or removal of conformationally altered proteins and/or molecules comprising a cross-β structure from a pharmaceutical composition or any of its constituents comprising a protein. Disclosed iss that unwanted and/or toxic side effects of pharmaceuticals are caused by proteins present in the pharmaceutical and adopting a cross-β structure conformation. Further disclosed is a method for detecting a protein and/or peptide comprising a cross-β structure in a pharmaceutical composition or any of its constituents comprising a protein, the method comprising: contacting the pharmaceutical composition or any of its constituents comprising a protein with at least one cross-β structure-binding compound resulting in a bound protein and/or peptide comprising a cross-β structure and; detecting whether bound protein and/or peptide comprising a cross-β structure are present in the pharmaceutical composition or any of its constituents comprising a protein. Further described are methods for removing cross-β structures from a pharmaceutical composition and controlling the manufacture of a pharmaceutical composition.

This invention relates to biology and medicine and, in particular, can be used in medicine to make a pharmaceutical composition for targeted delivery of biologically active substances into mitochondria, driven by proton electro-chemical potential in the mitochondria. This invention also relates to the method to affect an organism by the targeted delivery of biologically active compounds to mitochondria. The invention can be useful in treatment of diseases or disorders associated with not normal functioning of mitochondria, in particular diseases associated with increased production of free radicals and reactive oxygen species.

The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.